Spleen tyrosine kinase: a novel target for therapeutic intervention of rheumatoid arthritis
Authors:
- Malini BajpaiMBMalini Bajpai
- Puneet ChopraPCPuneet Chopra
- Sunanda G DastidarSDSunanda G Dastidar
- Abhijit RayARAbhijit Ray
- 30 April 2008
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 17 (5) , 641-659
Abstract
(2008). Spleen tyrosine kinase: a novel target for therapeutic intervention of rheumatoid arthritis. Expert Opinion on Investigational Drugs: Vol. 17, No. 5, pp. 641-659. doi: 10.1517/13543784.17.5.641Keywords
This publication has 105 references indexed in Scilit:
- Characterisation of a dendritic cell subset in synovial tissue which strongly expresses Jak/STAT transcription factors from patients with rheumatoid arthritisAnnals of the Rheumatic Diseases, 2007
- Clinical significance of IL-18, IL-15, IL-12 and TNF-α measurement in rheumatoid arthritisClinical Rheumatology, 2005
- The Orally Available Spleen Tyrosine Kinase Inhibitor 2-[7-(3,4-Dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5-ylamino]nicotinamide Dihydrochloride (BAY 61-3606) Blocks Antigen-Induced Airway Inflammation in RodentsThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Osteoclast differentiation and activationNature, 2003
- Lymphatics Make the BreakScience, 2003
- Syk Expression and Novel Function in a Wide Variety of TissuesBiochemical and Biophysical Research Communications, 2001
- A Critical Role for Syk in Endothelial Cell Proliferation and MigrationBiochemical and Biophysical Research Communications, 2001
- Induction and Suppression of Collagen-Induced Arthritis Is Dependent on Distinct Fcγ ReceptorsJournal of Experimental Medicine, 2000
- Systematic variation in gene expression patterns in human cancer cell linesNature Genetics, 2000
- RANK Is the Essential Signaling Receptor for Osteoclast Differentiation Factor in OsteoclastogenesisBiochemical and Biophysical Research Communications, 1998